Circulation: Cardiovascular Interventions最新文献

{"title":"Contrast-Derived Index of Microcirculatory Resistance (cIMR): A Novel Index for Measuring Coronary Microvascular Resistance.","authors":"Domenico Galante, Ciro Pollio Benvenuto, Andrea Viceré, Simona Todisco, Chiara Giuliana, Vincenzo Viccaro, Pierpaolo Tarzia, Lazzaro Paraggio, Mattia Lunardi, Cristina Aurigemma, Enrico Romagnoli, Rocco Montone, Gennaro Capalbo, Carlo Trani, Filippo Crea, Francesco Burzotta, Antonio Maria Leone","doi":"10.1161/CIRCINTERVENTIONS.126.016489","DOIUrl":"https://doi.org/10.1161/CIRCINTERVENTIONS.126.016489","url":null,"abstract":"","PeriodicalId":10330,"journal":{"name":"Circulation: Cardiovascular Interventions","volume":" ","pages":"e016489"},"PeriodicalIF":7.4,"publicationDate":"2026-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147834355","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"One-Year Outcomes of Screen Failures for Transcatheter Tricuspid Valve Repair: Insights From the TriSelect Study.","authors":"Felix Rudolph, Arseniy Goncharov, Akhil Narang, Maria L Körber, Jyothy J Puthumana, S Christopher Malaisrie, Zhiying Meng, Abigail Baldrigde, Tanja K Rudolph, Kai P Friedrichs, Roman Pfister, James D Thomas, Max Potratz, Volker Rudolph, Charles J Davidson, Muhammed Gerçek","doi":"10.1161/CIRCINTERVENTIONS.125.016124","DOIUrl":"https://doi.org/10.1161/CIRCINTERVENTIONS.125.016124","url":null,"abstract":"<p><strong>Background: </strong>Observational registries have shown improved survival among patients with severe or greater tricuspid regurgitation (TR) undergoing transcatheter tricuspid valve repair (TTVr) compared with conservative management. However, it remains unclear whether this survival benefit persists when specifically comparing patients undergoing TTVr with those who screen failed.</p><p><strong>Methods: </strong>We conducted a retrospective analysis of 547 patients from the TriSelect registry evaluated for TTVr-either transcatheter tricuspid valve edge-to-edge repair or direct transcatheter tricuspid valve annuloplasty at 3 tertiary centers in the United States and Germany between 2016 and 2021. The end point of 1-year survival was stratified by treatment group (TTVr versus screen fail) and procedural success (residual TR ≤ moderate versus > moderate).</p><p><strong>Results: </strong>Of the 547 patients, 219 (41.9%) screen failed and 318 (58.1%) underwent TTVr (transcatheter tricuspid valve edge-to-edge repair, 61.6%; transcatheter tricuspid valve annuloplasty, 38.4%). Among treated patients, 224 (70.4%) achieved residual TR ≤ moderate. Unadjusted Kaplan-Meier-derived 1-year survival was significantly higher in patients who underwent TTVr compared with screen-fail patients (82.5% versus 68.4%, log-rank <i>P</i><0.001). In multivariable Cox proportional hazards analysis, treatment with TTVr was independently associated with lower 1-year mortality (hazard ratio, 0.40 [95% CI, 0.18-0.86]; <i>P</i>=0.020). Among treated patients, survival was significantly higher in those with residual TR ≤ moderate versus those with greater than moderate residual TR (88.0% versus 69.2%, unadjusted log-rank <i>P</i>=0.005). Notably, in patients with residual TR > moderate, there was no survival benefit compared with screen-fail patients (unadjusted log-rank <i>P</i>=0.74).</p><p><strong>Conclusions: </strong>In this registry-based analysis, TTVr was associated with improved 1-year survival compared with screen-fail patients, but only when TR was reduced to moderate or less. These findings highlight the critical importance of achieving procedural success with a TTVr along with early referral and transcatheter tricuspid valve intervention device selection.</p>","PeriodicalId":10330,"journal":{"name":"Circulation: Cardiovascular Interventions","volume":" ","pages":"e016124"},"PeriodicalIF":7.4,"publicationDate":"2026-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147834400","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Postapproval Study Outcomes of Muscular Ventricular Septal Defect Closure With the Amplatzer Muscular VSD Occluder.","authors":"Athar M Qureshi, Henri Justino, Carl Owada, Mohammed Numan, Makram Ebeid, Thomas J Forbes, David Nykanen, Daisuke Kobayashi, Jillian Kolles, Dan Gutfinger, David Balzer","doi":"10.1161/CIRCINTERVENTIONS.125.016121","DOIUrl":"https://doi.org/10.1161/CIRCINTERVENTIONS.125.016121","url":null,"abstract":"<p><strong>Background: </strong>The Amplatzer Muscular Ventricular Septal Defect (VSD) Occluder (Abbott Structural Heart, Plymouth, MN) was approved by the US Food and Drug Administration in 2007. As a condition of approval, a postapproval study was required to further evaluate its safety and effectiveness. This study reports the clinical outcomes from the postapproval study over 5 years of follow-up.</p><p><strong>Methods: </strong>Patients with complex congenital muscular VSDs at high risk for surgical closure were enrolled between May 2008 and February 2020 in the United States and Canada. The primary effectiveness end points were technical implant success, acute procedure shunt-closure success, and 1-year shunt-closure success. The primary safety end point was the proportion of patients with any serious adverse event within 12 months of the procedure.</p><p><strong>Results: </strong>A total of 92 patients (median age, 2 years; 50 females) were enrolled in the study. Technical implant success was achieved in 93.8% of patients, and acute shunt-closure success was achieved in 78.0%. Successful shunt closure at 1-year was 94.4% and increased to >98% between 2 and 5 years. Within 12 months of the procedure, all-cause serious adverse events occurred in 47 of the 90 (52.2%) patients which included 7 device-related and 23 procedure-related serious adverse events. Between 1 and 5 years, there was 1 additional device- and procedure-related serious adverse event.</p><p><strong>Conclusions: </strong>This postapproval study demonstrates that transcatheter muscular VSD closure with the Amplatzer Muscular VSD Occluder is a safe and effective therapy for the treatment of complex congenital muscular VSDs in patients who are at high-risk for surgical closure.</p><p><strong>Registration: </strong>URL: https://www.clinicaltrials.gov; Unique identifier: NCT00647387.</p>","PeriodicalId":10330,"journal":{"name":"Circulation: Cardiovascular Interventions","volume":" ","pages":"e016121"},"PeriodicalIF":7.4,"publicationDate":"2026-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147834367","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Experience With a Novel Percutaneous LV Assist Device in High-Risk PCI: Primary Results From the SUPPORT I Study.","authors":"David E Kandzari, Andrea Mignatti, Annapoorna Kini, Garrett Wong, Gagan Singh, Azeem Latib, Ricardo Costa, Carlos M Campos, Alexandre Abizaid","doi":"10.1161/CIRCINTERVENTIONS.125.016010","DOIUrl":"https://doi.org/10.1161/CIRCINTERVENTIONS.125.016010","url":null,"abstract":"<p><strong>Background: </strong>An early feasibility study was conducted to evaluate the performance of a low-profile, microaxial percutaneous ventricular assist device (pVAD; Supira Medical, Los Gatos, CA) capable of up to 5.5 L/min flow to provide hemodynamic support in high-risk percutaneous coronary intervention.</p><p><strong>Methods: </strong>A prospective, single-arm feasibility study using the Supira pVAD in high-risk percutaneous coronary intervention was performed at 4 centers in the United States. The primary feasibility end point was defined as successful initiation and maintenance of hemodynamic support without sustained hypotension or need for alternative mechanical circulatory support. The primary safety end point was the occurrence of major device-related adverse events attributed to the study device or procedure from the time of device insertion to removal.</p><p><strong>Results: </strong>Fifteen patients underwent elective high-risk percutaneous coronary intervention with hemodynamic support using the Supira pVAD system. Multivessel percutaneous coronary intervention was performed in 80% of cases, including unprotected left main revascularization (67%) and atherectomy and intravascular lithotripsy (60%). Technical and procedural success rates were 93.3% and 86.7%, respectively. The primary feasibility end point was achieved in all 15 patients (100%). The primary safety end point occurred in 1 patient (6.7%). By 90 days, there were 2 deaths unrelated to the study device. There were no bleeding events, vascular/limb complications requiring intervention, cardiac structural/valve injury, or stroke attributed to the study device.</p><p><strong>Conclusions: </strong>As an early feasibility study, treatment with the Supira pVAD demonstrated favorable performance and device-related safety. These findings add to existing experience with the Supira pVAD to support a forthcoming pivotal trial in high-risk percutaneous coronary intervention.</p><p><strong>Registration: </strong>URL: https://www.clinicaltrials.gov; Unique identifier: NCT06087575.</p>","PeriodicalId":10330,"journal":{"name":"Circulation: Cardiovascular Interventions","volume":" ","pages":"e016010"},"PeriodicalIF":7.4,"publicationDate":"2026-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147834406","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early Feasibility Study of a Novel Mechanical Circulatory Support Device for High-Risk PCI.","authors":"Kevin J Croce, Ajay J Kirtane, Matthias Götberg, David E Kandzari, Brian Bergmark, Hector Tamez, Margaret McEntagart, Andrew J P Klein, Rafael Cavalcante, Robert Yeh","doi":"10.1161/CIRCINTERVENTIONS.125.016457","DOIUrl":"https://doi.org/10.1161/CIRCINTERVENTIONS.125.016457","url":null,"abstract":"","PeriodicalId":10330,"journal":{"name":"Circulation: Cardiovascular Interventions","volume":" ","pages":"e016457"},"PeriodicalIF":7.4,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147811760","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Temporal Trends in Isolated and Concomitant Aortic Valve Replacement for Aortic Stenosis in Patients Aged <65 Years.","authors":"Tanush Gupta, Hannah R Murphy, Bharat Rawlley, Dhaval Kolte, Alyssa H Harris, Neal S Kleiman, Patrick O'Gara, Harold L Dauerman","doi":"10.1161/CIRCINTERVENTIONS.126.016826","DOIUrl":"https://doi.org/10.1161/CIRCINTERVENTIONS.126.016826","url":null,"abstract":"","PeriodicalId":10330,"journal":{"name":"Circulation: Cardiovascular Interventions","volume":" ","pages":"e016826"},"PeriodicalIF":7.4,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147811785","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Timing of Complete Revascularization in Patients With STEMI and Multivessel Disease: An Updated Meta-Analysis of Randomized Clinical Trials.","authors":"Mohammed A Elbahloul, Shrouk Ramadan, Eman E Labeeb, Shahed Aldalahmeh, Ahella Ismail A Mousa, Ahmed Elazab, Ahmed N Mohamed, Ahmad Elashery, Mehiar O El-Hamdani, Carl J Lavie, Gregg W Stone","doi":"10.1161/CIRCINTERVENTIONS.126.016601","DOIUrl":"https://doi.org/10.1161/CIRCINTERVENTIONS.126.016601","url":null,"abstract":"<p><strong>Background: </strong>The ideal timing for complete revascularization (CR) in patients with ST-segment-elevation myocardial infarction and multivessel disease is uncertain. This meta-analysis examined outcomes of immediate CR (ICR) versus staged CR (SCR).</p><p><strong>Methods: </strong>Four databases were searched for randomized controlled trials that compared ICR and SCR in ST-segment-elevation myocardial infarction and multivessel disease. The primary end points of interest were short-term and long-term all-cause mortality. Outcomes are presented as risk ratios for short-term outcomes and incidence rate ratios for long-term outcomes with 95% CIs.</p><p><strong>Results: </strong>The analysis included 9 randomized controlled trials in which 4213 patients were enrolled. Short-term all-cause mortality occurred in 2.0% of patients after ICR compared with 1.2% of patients after SCR (risk ratio, 1.66 [95% CI, 0.99-2.78], <i>P</i>=0.053; <i>I</i>²=0%). Short-term cardiac death was increased after ICR (risk ratio, 2.19 [95% CI, 1.08-4.44], <i>P</i>=0.03; <i>I</i>²=0%). At a median 1-year follow-up, all-cause mortality occurred in 4.7% of patients after ICR compared with 3.5% of patients after SCR (incidence rate ratio, 1.40 [95% CI, 0.97-2.03], <i>P</i>=0.07; <i>I</i>²=0%). No significant differences were identified between the ICR and SCR strategies at either short-term or long-term follow-up for other outcomes, including myocardial infarction, repeat revascularization, stent thrombosis, stroke, major bleeding, and the composite of major adverse cardiac or cerebrovascular events.</p><p><strong>Conclusions: </strong>In hemodynamically stable patients with ST-segment-elevation myocardial infarction and multivessel disease, an ICR strategy may increase short-term cardiac death compared with SCR, and the possibility of increased early and late all-cause mortality cannot be excluded. Despite some uncertainty, these results currently favor a staged CR strategy for most patients with ST-segment-elevation myocardial infarction and multivessel disease.</p><p><strong>Registration: </strong>URL: https://www.crd.york.ac.uk/PROSPERO/; Unique identifier: CRD420251163719.</p>","PeriodicalId":10330,"journal":{"name":"Circulation: Cardiovascular Interventions","volume":" ","pages":"e016601"},"PeriodicalIF":7.4,"publicationDate":"2026-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147764385","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Outcomes of Bail-Out Stenting After Drug-Coated Balloon Angioplasty: The International Multicenter BAILOUT Registry.","authors":"Mauro Gitto, Pier Pasquale Leone, Tuomas T Rissanen, Natasha Corballis, Gianmaria Calamita, Francesco Tartaglia, Andrea Buono, Marco Ferrone, Alfonso Ielasi, Siamion Pismiankou, Marco Luciano Rossi, Ioannis Merinopoulos, Vassilios S Vassiliou, Luigi Salemme, Mauro Chiarito, Michele Galasso, Michele Morosato, Kasper Kyhl, Giovanni Occhipinti, Jonathan Hinton, Elodi Bacci, Guido Vellucci, Marcello Marchetta, Francesca De Micco, Damiano Regazzoli, Antonio Mangieri, Thomas Johnson, Fabrizio Ugo, Gabriele Gasparini, Bernhard Reimers, Peter O'Kane, Giuseppe Massimo Sangiorgi, Giulio G Stefanini, Stefano Galli, Fernando Alfonso, Diego Arroyo, Manel Sabaté, Carlo Briguori, Tullio Tesorio, Kambis Mashayekhi, Diego Maffeo, Azeem Latib, Simon Eccleshall, Antonio Colombo","doi":"10.1161/CIRCINTERVENTIONS.125.016461","DOIUrl":"https://doi.org/10.1161/CIRCINTERVENTIONS.125.016461","url":null,"abstract":"<p><strong>Background: </strong>Drug-coated balloons (DCBs) are increasingly adopted in percutaneous coronary intervention. Bail-out drug-eluting stent (DES) implantation due to suboptimal immediate results after DCB angioplasty is not infrequent, and the clinical outcomes of percutaneous coronary intervention with DCB angioplasty followed by bail-out DES implantation remain unexplored. The aim of this study was to evaluate the safety of bail-out DES implantation following DCB angioplasty in percutaneous coronary intervention.</p><p><strong>Methods: </strong>The BAILOUT registry included consecutive patients undergoing bail-out DES implantation after DCB angioplasty at 17 European centers between 2011 and 2024. The primary end point was target lesion failure (TLF) at 1 year, defined as the composite of target lesion revascularization, target vessel myocardial infarction, and cardiac death. The TLF rate was compared with a performance goal of 7.0% for an upfront DES-only strategy, derived from a meta-analysis of contemporary randomized controlled trials.</p><p><strong>Results: </strong>A total of 733 patients were included, accounting for 5.5% of all DCB-based percutaneous coronary interventions. At 1 year, the cumulative TLF incidence in the overall population was 7.0% (95% CI, 5.2%-9.3%), which was comparable to the performance goal (<i>P</i>=0.916). This was mainly driven by target lesion revascularization (4.1%), while cardiac death and target vessel myocardial infarction occurred both in 1.9% of patients. The incidence of stent thrombosis was 0.6%. Independent predictors of 1-year TLF included lesion length (hazard ratio, 1.02 per mm increase [95% CI, 1.01-1.03]; <i>P</i><0.001), moderate-to-severe calcification (hazard ratio, 2.82 [95% CI, 1.48-5.40]; <i>P</i>=0.002), and the use of paclitaxel- versus sirolimus-coated balloons (hazard ratio, 1.99 [95% CI, 1.01-4.05]; <i>P</i>=0.048).</p><p><strong>Conclusions: </strong>In cases of suboptimal angiographic results after DCB angioplasty, bail-out DES implantation is safe, with no increased risk of TLF at 1 year compared with the expected performance goal for an upfront DES-only strategy.</p>","PeriodicalId":10330,"journal":{"name":"Circulation: Cardiovascular Interventions","volume":" ","pages":"e016461"},"PeriodicalIF":7.4,"publicationDate":"2026-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147764404","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Systematic Ambulatory ECG Monitoring for Preventing Life-Threatening Cardiovascular Events Following TAVR.","authors":"Quentin Fischer, Isabelle Nault, Pedro Cepas-Guillén, Marisa Avvedimento, Carla Benavent-Garcia, Emilie Pelletier-Beaumont, François Philippon, Josep Rodés-Cabau","doi":"10.1161/CIRCINTERVENTIONS.125.016288","DOIUrl":"https://doi.org/10.1161/CIRCINTERVENTIONS.125.016288","url":null,"abstract":"<p><strong>Background: </strong>Although ambulatory ECG (AECG) monitoring has been assessed after transcatheter aortic valve replacement (TAVR), its impact on life-threatening cardiovascular events remains unclear. This study aimed to evaluate whether systematic AECG monitoring after TAVR reduces life-threatening cardiovascular events during the first year of follow-up.</p><p><strong>Methods: </strong>The study included 1217 consecutive patients who underwent TAVR and were discharged without a permanent pacemaker. Of these, 211 consecutive patients received systematic 14-day AECG monitoring at discharge as part of the RECORD registry. The remaining 1006 patients who underwent TAVR within the 3 years before and after the registry period without systematic AECG monitoring constituted the control group. The primary end point was a composite of sudden cardiac death, syncope/presyncope due to symptomatic arrhythmias, or stroke at 1-year.</p><p><strong>Results: </strong>Baseline and procedural characteristics were similar between groups, except for a higher use of self-expandable valves in the control group (<i>P</i>=0.005). Systematic AECG monitoring was associated with a lower incidence of the primary end point (1.9% versus 6.6%; adjusted hazard ratio, 0.27 [0.10-0.74]; <i>P</i>=0.011), mainly driven by a lower rate of sudden death or arrhythmic syncope/presyncope (0.9% versus 4.0%; adjusted hazard ratio, 0.22 [0.05-0.89]; <i>P</i>=0.034). All sudden death cases occurred in the control group, at a median of 96 (33-235) days after TAVR. New-onset atrial fibrillation was diagnosed in 8.9% of the systematic AECG patients (versus 1.8% in the control group; adjusted hazard ratio, 5.31 [2.47-11.38]; <i>P</i><0.001), leading to new oral anticoagulation in 71.4% of cases. Stroke and permanent pacemaker implantation rates at 1 year were similar between groups, although permanent pacemaker implantation occurred earlier in the AECG group (25 versus 104 days; <i>P</i><0.001).</p><p><strong>Conclusions: </strong>Systematic AECG monitoring after TAVR enables earlier detection of severe arrhythmias and is associated with fewer life-threatening cardiovascular events within 1 year. These findings support the need for a randomized trial.</p><p><strong>Registration: </strong>URL: https://www.clinicaltrials.gov; Unique identifier: NCT04298593.</p>","PeriodicalId":10330,"journal":{"name":"Circulation: Cardiovascular Interventions","volume":" ","pages":"e016288"},"PeriodicalIF":7.4,"publicationDate":"2026-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147764356","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Subclinical Leaflet Thrombosis in Transcatheter SAPIEN 3 Ultra RESILIA Bioprosthetic Valves.","authors":"Antonin Trimaille, Marisa Avvedimento, Guylaine Gleeton, Juan Hernando Del Portillo, Carlos Giuliani, Pablo Vidal, Carlos Real, Jean-Michel Paradis, Siamak Mohammadi, Anthony Poulin, Frederic Beaupré, Jean Porterie, Dimitri Kalavrouziotis, Eric Dumont, Emilie Pelletier-Beaumont, Josep Rodés-Cabau","doi":"10.1161/CIRCINTERVENTIONS.125.016439","DOIUrl":"https://doi.org/10.1161/CIRCINTERVENTIONS.125.016439","url":null,"abstract":"","PeriodicalId":10330,"journal":{"name":"Circulation: Cardiovascular Interventions","volume":" ","pages":"e016439"},"PeriodicalIF":7.4,"publicationDate":"2026-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147764443","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}